12.49
24-1月-25 16:45:00
15 分の遅延
株式
-0.50
-3.85%
本日の幅
12.10 - 13.18
ISIN
N/A
ソース
NASDAQ
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
10 1 2025 08:00:00 提供 Nasdaq GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
08 1 2025 08:00:01 提供 Nasdaq GlobeNewswire